RenovoRx, Inc. — Form 8-K
Filed July 2, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 78/100
What the filing says
RenovoRx received notice on July 1, 2026, that it has been granted an additional 180-calendar-day compliance period (until December 28, 2026) to regain compliance with Nasdaq's $1.00 minimum bid price requirement (Nasdaq Listing Rule 5550(a)(2)). The company initially received a deficiency notice on December 31, 2025, with a 180-day cure period ending June 30, 2026. If the stock closes at $1.00+ per share for 10 consecutive business days by December 28, 2026, Nasdaq will confirm compliance; otherwise, delisting proceedings commence with potential appeal rights.
Why this rating
Second-chance reprieve from delisting is moderately significant for a $26.6M-cap company—failure in 6 months could trigger delisting and loss of Nasdaq listing, materially damaging equity value and market access.
Extracted items
View original filing on SEC.gov ↗
See more from July 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.